CHS-1701

DRUG3 trials

Sponsors

Coherus Oncology, Inc.

Conditions

BioequivalenceHealthyImmunity, Humoral

Phase 1

Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)

CompletedNCT02385851

Coherus Oncology, Inc.Bioequivalence

Start: 2015-02-28End: 2015-07-31Updated: 2015-08-13

Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®

CompletedNCT02418104

Coherus Oncology, Inc.Immunity, Humoral

Start: 2015-05-31End: 2015-12-31Updated: 2016-01-07

Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta

CompletedNCT02650973

Coherus Oncology, Inc.Healthy

Start: 2016-02-29End: 2016-06-30Updated: 2016-08-01

Related Papers

Biosimilar Pegfilgrastim-cbqv Demonstrated Similar Immunogenicity to Pegfilgrastim in Healthy Subjects Across Three Randomized Clinical Studies.

2022-01-164 citations

Pharmacokinetic and Pharmacodynamic Equivalence of Pegfilgrastim-cbqv and Pegfilgrastim in Healthy Subjects

Advances in Therapy2020-08-1318 citations

Randomized, single-blind, crossover study to assess the pharmacokinetic and pharmacodynamic bioequivalence of CHS-1701 to pegfilgrastim in healthy subjects.

Journal of Clinical Oncology2017-05-208 citations